Semaglutide Opioid Use Disorder Trial Opens Phase 2 Enrollment

What is the semaglutide opioid use disorder trial testing?

The study asks a narrow question with large implications: does adding semaglutide to standard medication treatment for opioid use disorder make people more likely to stop using illicit and nonprescribed opioids? According to the registry record for NCT06548490, the trial enrolls adults already in outpatient treatment who are receiving either buprenorphine or methadone maintenance. Semaglutide is being tested on top of that existing care, not as a replacement for it.

The design is randomized, double-blind and placebo-controlled, with a planned enrollment of 200 participants and a 12-week treatment period on a weekly administration schedule. The registry describes the comparator plainly as an injection containing no drug, which matters methodologically: an injectable placebo keeps participants and staff from guessing assignment based on how the treatment is given.

Follow-up is unusually intensive for a 12-week study. Participants attend the clinic weekly for urine drug screening, vital signs, pregnancy testing where applicable, and mental health and drug use questionnaires, and they also complete smartphone surveys delivered at set times. That combination of biological verification and repeated self-report is how the investigators intend to detect whether abstinence patterns actually shift.

Why researchers are studying GLP-1 drugs in addiction at all

Semaglutide, marketed by Novo Nordisk as Ozempic for type 2 diabetes and Wegovy for weight management, is a GLP-1 receptor agonist — a molecule that mimics glucagon-like peptide-1, a gut hormone involved in insulin release, gastric emptying and satiety signaling. GLP-1 receptors are not confined to the pancreas and gut. They are also present in brain regions involved in reward and motivation, which is the biological premise behind studying these drugs for behaviors that have nothing to do with blood sugar.

That premise has been circulating for years, largely on the strength of animal work and anecdotal reports from patients who said their alcohol or nicotine cravings faded while taking a GLP-1 drug. What has been missing is controlled human data in people with a diagnosed substance use disorder. A Phase 2 trial with a placebo arm, objective urine screening and a defined primary question is the kind of study that can start converting anecdote into evidence — or fail to.

It is worth being precise about what a Phase 2 trial is and is not. It is designed to look for a signal of activity and to gather safety information in a modest number of patients. It is not sized to establish that a drug works well enough for regulatory approval, and a registry listing is a statement of intent, not a result.

Readers tracking an existing prescription can use the semaglutide dosage calculator to keep their own records consistent with what their provider set, independent of anything happening in research.

According to the trial's registry listing, the study is recruiting 200 adults and will compare semaglutide with an injected placebo over a 12-week treatment period.

A second new GLP-1 trial: tirzepatide and intracranial pressure

Registered the same week, a Phase 4 trial at Duke University is testing tirzepatide — the dual GIP and GLP-1 receptor agonist sold by Eli Lilly as Mounjaro and Zepbound — in idiopathic intracranial hypertension, a condition in which pressure inside the skull rises without an identified cause and can threaten vision. The listing for NCT07191873 describes a randomized, double-blind, placebo-controlled study of 60 participants, randomized one-to-one.

The primary endpoint is the difference between groups in the 12-month change in intracranial pressure, analyzed by analysis of covariance with baseline pressure as a covariate and a significance threshold of 0.05, in the intention-to-treat population. That level of pre-specification is notable: the analysis plan is fixed in advance, which limits the room to reinterpret an ambiguous result after the fact.

Idiopathic intracranial hypertension is strongly associated with obesity, and weight reduction is already part of conventional management. That makes the trial's design question genuinely interesting — whether any pressure benefit reflects something beyond weight change is exactly the sort of thing a 12-month controlled comparison is built to probe.

For those on a prescribed tirzepatide protocol, the tirzepatide dosage calculator handles the arithmetic of translating a provider's instructions into syringe units.

The Duke tirzepatide study record specifies a randomized, double-blind, placebo-controlled design in 60 participants with the 12-month change in intracranial pressure as the primary endpoint. the Duke tirzepatide study record.

How this fits the wider GLP-1 research picture

These two registrations land in the middle of a broad expansion of GLP-1 research into conditions far from the original indications. Recent journal output includes work on semaglutide in polycystic ovary syndrome, incretin effects on testosterone in men with hypogonadism, GLP-1 exposure in chronic pancreatitis, and hepatic steatosis and fibrosis markers in metabolic dysfunction-associated steatotic liver disease. In JAMA Psychiatry, investigators reported an analysis of GLP-1 receptor agonist use and mortality and cardiovascular outcomes in people with serious mental illness.

The safety literature is expanding in parallel, and not always favorably. Published items this month include a case report in a German dermatology journal describing tirzepatide as a possible trigger of bullous pemphigoid, a cohort analysis of nonscarring alopecia in adults treated with GLP-1 drugs, and a continuing exchange in JAMA Ophthalmology over whether semaglutide is associated with non-arteritic anterior ischemic optic neuropathy, a form of sudden optic nerve injury. Case reports and observational cohorts cannot establish causation, but they are how signals surface.

There is also an editorial current pushing back on how these drugs are used in practice. A commentary in Diabetology International argued against inappropriate use of GLP-1-based antiobesity medications, framing the goal as appropriate weight reduction rather than simply appropriate prescribing — a distinction that speaks directly to the gray market and cosmetic-use pressures around this drug class.

Because much of the emerging GLP-1 safety literature is built from case reports, disciplined side-effect logging with dates is what turns a vague recollection into something a clinician can review.

Separately, an analysis published in JAMA Psychiatry examined GLP-1 receptor agonist use alongside mortality and cardiovascular outcomes in people with serious mental illness.

What remains unresolved

Everything that matters most is still open. Neither trial has posted results, and both are listed as recruiting. Twelve weeks is a short window in which to change opioid use patterns, and the durability of any effect after treatment stops is not something a 12-week study can answer. The trial also enrolls people already stabilized on buprenorphine or methadone, so its findings would speak to semaglutide as an add-on rather than a standalone approach.

No regulator has approved semaglutide for any substance use disorder, and none has approved tirzepatide for idiopathic intracranial hypertension. Anyone encountering these trials in coverage should read them as hypotheses being formally tested, which is a meaningfully different thing from an established use.

Trials like this one measure attendance and abstinence week by week, which is the clinical-research version of the adherence tracking many readers already keep for themselves.